|
| 35976398 | Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306. | Eur Radiol | 2023 |
| 37666855 | The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer. | Nat Commun | 2023 |
| 37490173 | Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients. | Breast Cancer Res Treat | 2023 |
| 38051184 | Digital Breast Tomosynthesis versus Digital Mammography for Detection of Early-Stage Cancers Stratified by Grade: A TOSYMA Subanalysis. | Radiology | 2023 |
| 37690320 | Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA). | Breast | 2023 |
| 37214906 | Pseudorabies virus hijacks DDX3X, initiating an addictive "mad itch" and immune suppression, to facilitate viral spread. | bioRxiv | 2023 |
| 37312086 | The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice. | BMC Cancer | 2023 |
| 37075697 | Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry. | ESMO Open | 2023 |
| 37201751 | Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial. | Ann Oncol | 2023 |
| 37330436 | Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). | Virchows Arch | 2023 |
| 37260368 | Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany. | Int J Cancer | 2023 |
| 36750040 | Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer. | Oncol Res Treat | 2023 |
| 36807725 | Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL. | Breast Cancer Res Treat | 2023 |
| 36423347 | Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. | Leuk Lymphoma | 2023 |
| 36763171 | Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients. | J Cancer Res Clin Oncol | 2023 |
| 36194110 | Breast Density and Breast Cancer Screening with Digital Breast Tomosynthesis: A TOSYMA Trial Subanalysis. | Radiology | 2023 |
| 34292391 | Breast carcinomas of low malignant potential. | Virchows Arch | 2022 |
| 35583555 | VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results. | Clin Cancer Res | 2022 |
| 35350106 | Awareness and Availability of Routine Germline <i>BRCA1/2</i> Mutation Testing in Patients with Advanced Breast Cancer in Germany. | Breast Care (Basel) | 2022 |
| 35637412 | Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. | Br J Cancer | 2022 |
| 35570084 | Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259]. | Eur J Cancer | 2022 |
| 35747845 | Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. | Hemasphere | 2022 |
| 36512641 | Stress signaling boosts interferon-induced gene transcription in macrophages. | Sci Signal | 2022 |
| 35940054 | First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110). | Eur J Cancer | 2022 |
| 36145178 | Impaired Mucosal Homeostasis in Short-Term Fiber Deprivation Is Due to Reduced Mucus Production Rather Than Overgrowth of Mucus-Degrading Bacteria. | Nutrients | 2022 |
| 36356410 | A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE). | ESMO Open | 2022 |
| 36353562 | Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients. | Front Oncol | 2022 |
| 34953442 | Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. | Eur J Cancer | 2022 |
| 35158793 | Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy. | Cancers (Basel) | 2022 |
| 35251955 | Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial. | Front Oncol | 2022 |
| 35220309 | Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors. | Oncol Res Treat | 2022 |
| 34915530 | New Opportunities in Advanced Breast Cancer. | Oncol Res Treat | 2022 |
| 34818643 | The Future Role of PET Imaging in Metastatic Breast Cancer. | Oncol Res Treat | 2022 |
| 34431518 | Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). | Int J Cancer | 2022 |
| 32930387 | Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). | Int J Cancer | 2021 |
| 33743073 | Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046. | J Cancer Res Clin Oncol | 2021 |
| 33764808 | HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. | J Clin Oncol | 2021 |
| 33762647 | Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients. | Sci Rep | 2021 |
| 33647548 | Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). | Eur J Cancer | 2021 |
| 33758366 | The AP-1 transcription factors c-Jun and JunB are essential for CD8α conventional dendritic cell identity. | Cell Death Differ | 2021 |
| 35011579 | Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. | Cells | 2021 |
| 34524899 | Genomes of Novel <i>Myxococcota</i> Reveal Severely Curtailed Machineries for Predation and Cellular Differentiation. | Appl Environ Microbiol | 2021 |
| 34496363 | Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO. | Oncol Res Treat | 2021 |
| 34424267 | The early interferon catches the SARS-CoV-2. | J Exp Med | 2021 |
| 34569651 | Pro-atherogenic actions of signal transducer and activator of transcription 1 serine 727 phosphorylation in LDL receptor deficient mice via modulation of plaque inflammation. | FASEB J | 2021 |
| 34507244 | Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). | Eur J Cancer | 2021 |
| 34102639 | [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors. | Oncol Res Treat | 2021 |
| 34350900 | Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience. | Oncol Res Treat | 2021 |
| 34124936 | The Cyclin-Dependent Kinase 8 (CDK8) Inhibitor DCA Promotes a Tolerogenic Chemical Immunophenotype in CD4<sup>+</sup> T Cells via a Novel CDK8-GATA3-FOXP3 Pathway. | Mol Cell Biol | 2021 |
| 34237114 | Listeria monocytogenes infection rewires host metabolism with regulatory input from type I interferons. | PLoS Pathog | 2021 |